NCT06700057Recruiting
Clinical and Dosimetric Study of Patients Treated With 177Lu-PSMA-617 for Prostate Cancer.
Optimisation and Safety of an Innovative Nuclear Medicine Treatment: Clinical and Dosimetric Study of Patients Treated With 177Lu-PSMA-617 for Prostate Cancer.
Source: ClinicalTrials.gov · Last updated 30 Jan 2026
Brief summary (registry, in English)
Single-centre, retrospective and prospective observational study. This study aims to evaluate the dose delivered by radiation to the tumour and organs at risk, as a factor predicting response and the appearance of toxicities. Dosimetric calculations are made for each treatment using scintigraphic images acquired following injection of 177Lu-PSMA-617.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 50 (estimated)
- First submitted
- 19 Nov 2024
- Start date
- 1 Nov 2023
- Primary completion date
- 30 Nov 2026
- Lead sponsor
- Institut Bergonié
- Diseases
- Prostate cancer
- NCT number
- NCT06700057
What you commit to
- Study type: Observational
- Planned participants: 50
- From 1 Nov 2023 to the primary completion date, 30 Nov 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- None
Who the study is looking for
- Patient aged 18 and over.
- Patient with indication for or having started or completed treatment with 177Lu-PSMA-617 since 01/11/2023:
- Progressive, metastatic, castration-resistant prostate cancer,
- overexpressing prostate specific membrane antigen (PSMA)
- treated with taxane chemotherapy and at least one 2nd generation hormone therapy (apalutamide, enzalutamide, darolutamide, abiraterone-prednisone).
- Patient able to lie still for 1 hour for image acquisition.
- Patient's place of residence \< 2 hours' drive from the Institut Bergonié.
- Patient has not expressed any opposition to the use of his/her medical data for research purposes.
Age in the registry: 18 years to - · Sex: Male · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Institut Bergonie Coordinator of this site? Confirm its status | Bordeaux | France | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.